Aqua Pharmaceuticals, LLC, a specialty pharmaceutical company, acquires, develops, and markets drugs indicated for the treatment of dermatological conditions. The company has leading branded prescription drugs in four therapeutic categories that include acne, steroid-responsive dermatoses, actinic keratoses, and seborrheic dermatitis.
An essential element in Aqua's strategy for strong, sustainable growth is to build beyond the current product portfolio by developing, licensing, and acquiring products for the treatment of skin conditions. Importantly, Aqua looks to expand its opportunities through product development, in-licensing, co-promotion, product or company acquisition, and partnerships.
In December 2013, Almirall S.A. entered into a definitive agreement to acquire Aqua Pharmaceuticals. Almirall is a pharmaceutical company committed to provide valuable medicines through its own R&D efforts together with external partnerships, licenses, and collaborations. Through seeking innovative medicines, Almirall aims to be a relevant player in dermatology, in addition to having a strong interest in gastroenterology and pain. With more than 3,000 employees in 23 countries, Almirall generated total revenues of €825 million in 2013. The company was founded in 1943 and is headquartered in Barcelona, Spain. The stock is traded on the Spanish stock exchange (ticker: ALM).
Almirall will work closely with Aqua's management team to expand upon the company's current product portfolio through an active program of acquisition, licensing, and internal drug development. If you have interest in discussing corporate and business development opportunities that you believe may be of interest to Aqua, please submit the Business Opportunity Inquiry form at right or contact us at:
707 Eagleview Blvd., Suite 200
Exton, PA 19341
Business Opportunity Inquiry
Required fields are marked with *